Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Bernard R Brooks · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · 2023 · $745,223 — Constant pressure simulation on GPUs Most molecular dynamics packages do not handle the non-pairwise contributions to the virial, resulting in non-rigorous isobaric ensemble simulations. Through the derivation of these contributions and its implementation via the Langevin Piston algorithm in our ap…
Ralph S Baric · UNIV OF NORTH CAROLINA CHAPEL HILL · 2023 · $2,950,055 — Abstract. The UNC Center for Excellence in SARS-CoV2 Serologic Research uses basic and applied research strategies to improve our understanding of the molecular and cellular mechanisms driving serological and humoral immune responses after SARS-CoV2 infection. Our overall goals are to 1) characteriz…
DWAYNE W GODWIN · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2023 · $429,824 — PROJECT SUMMARY Alcohol withdrawal (WD) produces a range of dangerous clinical symptoms, including intense seizures. Hyperexcitability underlying seizures is produced by an array of intrinsic membrane properties that are disrupted by ethanol (EtOH). Prior work has demonstrated that chronic EtOH expo…
GUIRONG WANG · UPSTATE MEDICAL UNIVERSITY · 2023 · $203,750 — More than 4.8 million people have died due to coronavirus disease 2019 (COVID-19) in less than two years. COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Morbidity and mortality following SARS-CoV-2 infection are predominantly due to a robust…
Dan H. Barouch · BETH ISRAEL DEACONESS MEDICAL CENTER · 2023 · $897,731 — ABSTRACT The development of a SARS-CoV-2 vaccine may be critical to ending the COVID-19 pandemic. However, a critical gap in knowledge is the lack of understanding of correlates of SARS-CoV-2 immunity in humans. Our preliminary data suggest that antibodies correlate with protection following vaccina…
Mary N. Carrington · DIVISION OF BASIC SCIENCES - NCI · 2021 · $603,715 — HLA class I molecules present antigenic peptides to CD8 T cells, eliciting an adaptive immune response. Peptide loading of HLA class I molecules takes place within the peptide loading complex (PLC) and tapasin is a critical component of the PLC, which performs its peptide "editing" function by assoc…
Jordan L Meier · DIVISION OF BASIC SCIENCES - NCI · 2021 · $1,900,684 — The overarching goal of this project is to define how environmental cues that impact protein and nucleic acid-based signaling, including but not limited to the epigenetic regulation of gene expression, contribute to cancer development and progression. To facilitate these studies we are developing ne…
Steven M Wolinsky · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2021 · $300,000 — PROJECT SUMMARY The innate immune recognition of dengue virus infection triggers antiviral immune responses; however, there is little information about how the virus regulates these measures or how these responses affect dengue virus (DENV) disease pathogenesis and immunity. System biology approa…
Nir Hacohen · MASSACHUSETTS GENERAL HOSPITAL · 2021 · $421,903 — Project Summary The overall objective of the U19 is to discover the role of the PD-1 pathway in human immunity by studying the effects of therapeutic PD-1 blockade on immune responses to chronic viruses (Project 1) and preventive vaccines (Project 2). To monitor adaptive immune responses in patients…
Joanna Phillips · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2021 · $180,967 — PROJECT SUMMARY The UCSF Brain Tumor SPORE Biospecimen/Pathology Core provides staff and technology dedicated to the procurement, processing, storing, distribution, and histopathologic analysis of high-quality brain tumor biospecimens for translational science research. Our mission is to enhance bio…
DONALD Lawrence SIEGEL · UNIVERSITY OF PENNSYLVANIA · 2021 · $235,793 — SUMMARY CORE B: GMP CELL and RNA MANUFACTURING Core B is the Clinical Cell and Vaccine Production Facility (CVPF). The CVPF is a Foundation for the Accreditation of Cellular Therapy (FACT)-accredited, Good Manufacturing Practices (GMP) compliant cell and RNA manufacturing facility. This facility …
Karen S. Anderson · YALE UNIVERSITY · 2021 · $437,838 — SUMMARY Human papillomavirus (HPV)-associated neck squamous cell carcinoma (HNSCC) represents an increasing proportion of HNSCC. The incidence of HPV+ HNSCC has dramatically increased over the last 2 decades and in 2012 surpassed uterine cervical cancer as the most common HPV-related malignancy in t…
XU LI · ZYMERON CORPORATION · 2021 · $300,000 — Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery …
MARK LEWIS · BIOQUAL, INC. · 2021 · $530,959 — The development of effective HIV vaccines and other prevention strategies relies on the use of nonhuman primates (NHPs) in preclinical studies. To meet this need, the Simian Vaccine Evaluation Units (SVEUs) provide NHP resources that primarily support preclinical evaluation of AIDS vaccines and prev…
JULIE AKE · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $10,950,000 — The NIAID Division of AIDS and the U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research (WRAIR), U.S. Army Medical Research and Development Command (MRDC) remain committed to the common objective of developing a safe and effective vaccine for HIV/AIDS. The Agencies recog…
Genevieve Giny Fouda Amou ou · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $714,185 — ABSTRACT – Project 2 Globally, about 600,000 young adults (15-24 years of age) became infected with HIV-1 in 2017. Young women age 15-19 years are most affected, and HIV-infection in this age group continue to rise. Therefore, a vaccine to prevent HIV acquisition in young adults remains a top priori…
LOUISE C. SHOWE · WISTAR INSTITUTE · 2021 · $221,010 — PROJECT SUMMARY – GENOMICS SHARED RESOURCE The Genomics Shared Resource (GSR) provides state-of-the-art infrastructure and support for integrated functional genomics studies of Cancer Center (CC) investigators. The highly trained staff and their efforts to maintain costs without diminishing service,…
Frederick Porter · DUKE UNIVERSITY · 2021 · $1,280,922 — Project 2: Current Good Manufacture Practices (CGMP) Production of Nucleoside-Modified mRNAs Encoding HIV-1 Envelopes This IPCAVD grant seeks to develop and evaluate mRNA as an HIV-1 vaccine platform. Project 2 will oversee the manufacture of two nucleoside-modified mRNAs by current good manufacturi…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2021 · $610,481 — Project Summary Administrative Core This Phase II COBRE will continue our center’s work to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approaches for unde…
John H Adams · UNIVERSITY OF SOUTH FLORIDA · 2021 · $1,036,232 — Project Summary/Abstract Plasmodium vivax is the second leading cause of malaria and the most prevalent cause of malaria outside of Africa. The estimated cost of the global burden of vivax malaria is $1.4 - $4 billion per year and more people live at risk worldwide from P. vivax than P. falciparum. …